GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition Main Findings: Visugromab, a GDF-15 blocking antibody, is tolerable and elicits clinical responses in combination with nivolumab.Concept: GDF-15 may represent a mechanism of anti-PD-1 resistance that ...

ICYMI: "Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours" - a #ResearchWatch summary of a study by Ignacio Melero, Eugen Leo, and colleagues #ClinicaNavarra #CIMA_unav #visugromab #CatalYm

doi.org/10.1158/2159...

CatalYm shows potential of visugromab for treating cachexia - PharmaTimes New findings presented at international SCWD conference

#oncology #cancercare #CatalYm #GDF15neutralisingmonoclonalantibody #visugromab #cachexia #cancerinducedcachexia #cachexiatreatment #GDFATHERtrial #preclinicalresearch #cancerpatients #humanizedmonoclonalantibody #monoclonalantibody #visugromabtreatment
pharmatimes.com/news/catalym...